Atazanavir: a review of its use in the management of HIV-1 infection. (Q34984899)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

review article

1 reference

title

Atazanavir: a review of its use in the management of HIV-1 infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

2

Sohita Dhillon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Katherine F Croom

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

1 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

1107-1140

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19496633%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-200969080-00009

30 January 2020

exact match

0 references

cites work

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200969080-00009

Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers

21 January 2018

1 reference

12 December 2020

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice

1 reference

12 December 2020

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis

1 reference

12 December 2020

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

1 reference

12 December 2020

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

1 reference

12 December 2020

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

1 reference

12 December 2020

Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes.

1 reference

12 December 2020

Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.

1 reference

12 December 2020

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

1 reference

12 December 2020

Low atazanavir concentrations in cerebrospinal fluid

1 reference

12 December 2020

Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy

1 reference

12 December 2020

Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients

1 reference

12 December 2020

Virological failure and subsequent resistance profiles in individuals exposed to atazanavir

1 reference

12 December 2020

No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial

1 reference

12 December 2020

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen

1 reference

12 December 2020

Predictors of virological response to atazanavir in protease inhibitor-experienced patients

1 reference

12 December 2020

Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations

1 reference

12 December 2020

A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients

1 reference

12 December 2020

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients

1 reference

12 December 2020

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

1 reference

12 December 2020

Metabolic issues associated with protease inhibitors

1 reference

12 December 2020

Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects

1 reference

12 December 2020

Darunavir: in the treatment of HIV-1 infection

1 reference

12 December 2020

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

1 reference

12 December 2020

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen

1 reference

12 December 2020

Reviving protease inhibitors: new data and more options.

1 reference

12 December 2020

Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients

1 reference

12 December 2020

Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study

1 reference

12 December 2020

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

1 reference

12 December 2020

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

1 reference

12 December 2020

Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection

1 reference

12 December 2020

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients

1 reference

12 December 2020

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION S

1 reference

12 December 2020

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

CD4+ count-guided interruption of antiretroviral treatment

1 reference

12 December 2020

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients

1 reference

12 December 2020

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

12 December 2020

Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones

1 reference

12 December 2020

Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

12 December 2020

Drug interactions between HIV protease inhibitors and acid-reducing agents.

1 reference

12 December 2020

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia

1 reference

12 December 2020

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients

1 reference

12 December 2020

Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically

1 reference

12 December 2020

Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients

1 reference

12 December 2020

Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial

1 reference

12 December 2020

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

1 reference

12 December 2020

Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir

1 reference

12 December 2020

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses

1 reference

12 December 2020

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

1 reference

12 December 2020

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

12 December 2020

Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain

1 reference

12 December 2020

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

1 reference

12 December 2020

Atazanavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

1 reference

12 December 2020

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

1 reference

12 December 2020

Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study

1 reference

12 December 2020

Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers

1 reference

12 December 2020

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

12 December 2020

Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

1 reference

12 December 2020

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir

1 reference

12 December 2020

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

1 reference

12 December 2020

Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

1 reference

12 December 2020

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

1 reference

12 December 2020

Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

1 reference

12 December 2020

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

1 reference

12 December 2020

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

1 reference

12 December 2020

Efficacy and safety of once-daily regimens in the treatment of HIV infection

1 reference

12 December 2020

Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers

1 reference

12 December 2020

Tipranavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Limitations of current HIV therapies: opportunities for improvement

1 reference

12 December 2020

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

1 reference

12 December 2020

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir

1 reference

12 December 2020

Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy

1 reference

12 December 2020